Physician profile
Leila Darki
NPI 1033472931
$79,667.61
in general payments reported to CMS, 2019-2025
18 companies · $56K in 2025
The $56K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,170 · 2020: $930 · 2021: $0.83 · 2022: $1,934 · 2023: $4,728 · 2024: $10K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $7,998 · Food and Beverage: $3,823 · Honoraria: $3,413 · Education: $29.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,610.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,760.00 |
| Travel and Lodging | $7,998.04 |
| Food and Beverage | $3,822.96 |
| Honoraria | $3,412.50 |
| Education | $29.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $29,848.10 | 2022-2025 | Rystiggo, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $21,776.01 | 2020-2025 | Ultomiris |
| Amgen INC. | $7,999.20 | 2025 | Uplizna |
| Biogen, INC. | $4,547.71 | 2019 | |
| Amicus Therapeutics, INC. | $3,649.26 | 2024-2025 | Pombiliti, Opfolda |
| Amylyx Pharmaceuticals, INC. | $3,450.40 | 2023-2024 | Relyvrio |
| Genzyme Corporation | $3,295.00 | 2025 | |
| Argenx US, INC. | $3,050.70 | 2022-2023 | Vyvgart |
| Ucb Sa | $1,408.51 | 2019 | |
| Akcea Therapeutics, INC. | $269.28 | 2019-2020 | |
| Grifols USA, LLC | $124.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.20 | 2025 | Hyqvia |
| Tanabe Pharma America, INC. | $41.21 | 2019-2024 | |
| Sk Life Science, INC. | $34.71 | 2023 | |
| Alnylam Pharmaceuticals INC. | $27.26 | 2024 | Onpattro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $21.99 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.29 | 2025 | Wainua |
| Travere Therapeutics, INC. | $4.15 | 2021-2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leila Darki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.